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Abstract
Due to their excellent biocompatibility, carbon nanoparticles have been widely investigated
for prospective biomedical applications. However, their impact on an organism with pro-
longed exposure is still not well understood. Here, we performed an experiment investigat-
ing diamond, graphene oxide and graphite nanoparticles, which were repeatedly
administrated intraperitoneally into Wistar rats for four weeks. Some of the animals was sac-
rificed after the last injection, whereas the rest were sacrificed twelve weeks after the last
exposure. We evaluated blood morphology and biochemistry, as well as the redox and
inflammatory state of the liver. The results show the retention of nanoparticles within the
peritoneal cavity in the form of prominent aggregates in proximity to the injection site, as
well as the presence of some nanoparticles in the mesentery. Small aggregates were also
visible in the liver serosa, suggesting possible transportation to the liver. However, none of
the tested nanoparticles affected the health of animals. This lack of toxic effect may suggest
the potential applicability of nanoparticles as drug carriers for local therapies, ensuring
accumulation and slow release of drugs into a targeted tissue without harmful systemic side
effects.
Introduction
Carbon is the most widespread element in all living organisms and thus carbon nanoparticles,
due to their excellent biocompatibility, are an attractive alternative to traditionally used anti-
cancer drugs and may be applicable in drug delivery systems.
We studied the biological properties of three different forms of carbon nanoparticles—dia-
mond (DN), graphene oxide (GO) and graphite (GR). They differ in shape, proportion of
chemical bonds, atomic hybridization (sp2 for GO and GR, and sp3 for DN) and functional
groups; these factors affect their electrochemical and redox potential and influence their behav-
ior in biological models [1–3]. DN, GO and GR have been reported to be non-toxic and
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biocompatible moieties [4–9], on the other hand showing antiproliferative and anticancer
properties against tumor cells in in vitromodels [10,11].
The excellent biocompatibility of DN was demonstrated has been in vivo studies on mice
and rats, showing no toxic effects and no impact on the immune system [4,5]. DN has been
also reported to be a good intracellular transporter of drugs like chemotherapeutics [12]. More-
over, DN have antiangiogenic properties, which lead to tumor growth inhibition [10], making
DN a promising anticancer agent since angiogenesis is one of the major factors promoting
tumor development. DN and GR, even in high doses, are non-toxic to developing chicken
embryos, although the mRNA expression of basic fibroblast growth factor was downregulated
and heart vascularization and vessel density were diminished [13]. Furthermore, in studies
using a Caenorhabditis elegans (roundworm) model, GR similarly did not reveal any toxic
effects [6]. Even exposure of rats to GR in inhaled air did not induce an inflammatory state in
lungs [7]. GO is a relatively new nanomaterial, and has recently attracted interest in the bio-
medical field [2,14]. GO in a formulation with dextran was reported to be a stable and promis-
ing agent for MRI bioimaging [15]. GO is also considered as a new hope and future for
regenerative medicine and tissue engineering since GO composites are ultra-strong, lightweight
and can successfully reinforce biodegradable materials [16]. Different in vitro studies showed
that graphene has anticancer and antiproliferative properties [17,18], and may have cytotoxic
effect on normal, healthy cells [19], however, it depends on the form of used graphene, as well
as on the production method. Similarly, antibacterial activity is also dependent on the form of
used graphene [2]. Chowdhury et. al. [20] reported that GO functionalized with dextran had
no adverse effect on hematological components in vitro, and did not induce endothelial dys-
function during in vivo studies with the hamster model. In vivo studies in mice, conducted by
Yang et al. [8], demonstrated that GO has no toxic effects; however, they suggested that the
administration route has an important impact on the final effect. The work of Ma-Hock et al.
[7] contributed to this statement since, in their experiment, there was inflammation in the
lungs of mice after GO exposure in inhaled air. Kanakia et al. [9] performed studies on rats,
employing dextran-functionalized GO administrated intravenously in a wide range doses (1 to
500 mg/kg), demonstrating no effect on respiratory, cardiovascular or hematological indices at
doses< 125 mg/kg. Minor changes in some organs (e.g. the liver) were reported, which were
associated with GO particle accumulation. Longer exposure (30 days) showed only a negligible
presence of GO in examined organs, suggesting removal and extraction through the feces.
Nevertheless, the majority of the in vivo results are based on short-term exposure to nano-
particles, by measuring acute responses, while the long-lasting effects have not been broadly
investigated [5,21,22]. The excretion rate of DN, GO and GR is not certain since multiple
reports have suggested potential accumulation of nanoparticles or their formulations in tissues
[5,8,23–25]. Thus, it is essential to study the possible toxicity of prolonged carbon nanoparticle
accumulation, which may remain in treated tissues for a long time after administration. Nano-
particle retention might be considered an advantage for creating drug delivery systems meant
to stay within the target tissue, assuring the optimal drug concentration without harmful sys-
temic reactions. The possible slow spread and circulating routes of nanoparticles should be also
considered. The liver is the primary organ responsible for the accumulation of multiple sub-
stances, as it breaks down or modifies toxins, and is highly dependent on the oxidation capabil-
ity of hepatocytes [26]. Therefore, the liver may be susceptible to damage caused by
nanoparticles, which after accumulation, can be gradually passed to blood vessels and trans-
ported to the liver, triggering oxidative stress and inflammation [27].
We hypothesized that after multiple intraperitoneal injections, nanoparticles will be
retained within the peritoneum, adhered to internal organs, and they will also penetrate into
the liver since the majority of blood circulation within the peritoneal cavity, especially within
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mesentery, leads directly to the liver via veins connected to the hepatic portal vein. The hypoth-
esis presumes long-lasting effects on animal health. The objective of this study was to evaluate
systemic responses to the long-term exposure to bare nanoparticles. Consequently, we evalu-
ated the growth and health status of rats after 4 weeks of injections followed up by a growth
period of 8 weeks. The measurements included blood morphology and biochemical parame-
ters, changes in oxidative status of the liver measured by total glutathione levels and lipid oxi-
dation, as well as the inflammatory state assessed by C-reactive protein measurements and
multiple cytokine levels.
Material & Methods
Ethics statement
The experimental procedures were performed in accordance with Polish legal regulations con-
cerning experiments on animals (Dz. U. 05.33.289). The experimental protocols were accepted
by the III Local Ethics Commission for Experimentation on Animals at Warsaw University of
Life Sciences, Poland.
Nanoparticles
ND and GR were obtained from Skyspring Nanomaterials Inc. (Houston, TX, USA). Both
nanomaterials were produced by the explosive method and synthesized to 3–4 nm. According
to the manufacturer, the purity was>95% for DN and> 93% for GR, and the specific surface
area was 282 m2/g for DN and 540–650 m2/g for GR.
GO was obtained from the Institute of Electronic Materials Technology (Warsaw, Poland),
produced by a modified Hummers method from graphite flakes (Asbury Carbons, Asbury,
USA). The detailed data of the production method and a characteristic, including FTIR analy-
sis, are presented in Kurantowicz et al. [2].
Pure powders of nanoparticles were suspended in sterile saline solution at a concentration
of 500 mg/L and sonicated at 550 W/m2 for 1 h in an ultrasonic bath (Sonorex Super RK 514H,
Bandelin Electronic, Germany) prior to injection.
Visualization of nanoparticles. The size and shape of nanoparticles were inspected using
transmission electron microscopy (TEM: JEM-2000EX; JEOL, Tokyo, Japan) at 80 keV. Images
were captured with a Morada 11 megapixel camera (Olympus Soft Imaging Solutions GmbH,
Münster, Germany). Droplets of nanoparticles solutions were placed onto formvar-coated cop-
per grids (Agar Scientific, Stansted, UK) and immediately after air-drying the grids were
inspected by TEM (Fig 1).
Zeta potential measurements. The Zeta potential of suspended nanoparticles were
determined after 120 seconds of stabilization at 25°C by the Dynamic Laser Scattering electro-
phoretic method with Smoluchowski approximation by Zetasizer Nano-ZS90 (Malvern,
Worcestershire, UK). Each measurement was repeated 3 times. The mean Zeta potentials of
Fig 1. TEM pictures of diamond (A), graphene oxide (B) and graphite (C). Scale bar indicates 200 nm.
doi:10.1371/journal.pone.0144821.g001
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the DN, GO and GR solutions in 0.9% NaCl were -15.8 mV, – 8.80 mV and 12,5 mV, respec-
tively (Table 1).
Animals
Animal maintenance. Forty female Wistar Crl:WI(Han) (strain ID number 2308816 in
Rat Genome Database) outbred rats (6 weeks of age, average body weight [BW] 124 ± 19 g)
were randomly divided into four equal groups (placebo, ND, GO, GR) and kept in separate
cages for 4 to 12 weeks. The animals were housed in polycarbonate cages with steel wire tops.
They were kept under standard conditions at a room temperature of 22 ± 2°C, 50–60% humid-
ity and 12:12 light:dark cycle. The animals had free access to fresh water and dry pellet feed
(Labofeed B standard, Morawski, Poland). Animal behavior, food and water intake and hair/
skin condition were monitored.
Nanoparticle administration. Rats were administrated multiple intraperitoneal injections
of 1 ml of physiological saline (0.9% NaCl) for the placebo group and 1 ml of the nanoparticle
suspension in physiological saline for the remaining groups (ND group, GO group GR group).
The injections were given for 4 weeks at three-day intervals (in total eight injections). The
nanoparticle suspensions were given at a concentration of 500 mg/L, equivalent to 4 mg of
nanoparticles/kg body weight. Some of the animals (seven from each group) were terminated 3
days after the last injection, while the rest (three from each group) were maintained for an
additional eight weeks (12 weeks of the experiment in total) in order to evaluate the systemic
response to long-term exposure to nanoparticles accumulated in the body.
Animal euthanasia. After 4 or 12 weeks, the animals were fasted for 12 hours then eutha-
nized by the inhalation of isoflurane (Forane, USP, Baxter, Poland). Blood samples were col-
lected from the heart by cardiac puncture (see below). Photographs of the general outlook of
the rat interior were taken immediately after sacrifice. Livers were excised, washed with phos-
phate buffered saline, weighed and stored at -80°C for further analysis.
Blood morphology. One milliliter of blood was collected into tubes coated with K3-EDTA
as an anticoagulant (Equimed, Krakow Poland). Complete blood was used for blood morphol-
ogy examination, performed by automated hematologic analyzer (Abacus Junior Vet, Diatron
Group, Budapest, Hungary). The following complete blood parameters were examined: num-
ber of white blood cells (WBC, 109/L) and their subpopulation (all in 109/L)—lymphocytes
(LYM), granulocytes (GRA), monocytes (MID), number of red blood cells (RBC, 1012/L),
plasma hemoglobin concentration (HGB, g/dL), hematocrit (HCT, %), number of platelets
(PLT, 109/L), relative distribution width of the red cell population (RDW, % of covariance),
mean red blood cell corpuscular volume (MCV, fL), mean erythrocyte hemoglobin concentra-
tion (MCH, pg), mean cell hemoglobin concentration (MCHC, g/dL), mean platelet volume
(MPV, fL), relative distribution width of the thrombocyte population (PDWc, in %) and plate-
letcrit (PCT, in %).
Blood serum biochemical indices. One milliliter of blood was collected into tubes with a
clot activator (Equimed) for serum determinations. Serum was centrifuged at 3800 x g for 8
minutes at 4°C (Sorvall1 ST16, Thermo Fisher Scientific, Waltham, MA, USA). Biochemistry
Table 1. An average size and Zeta potential of diamond (DN), graphene oxide (GO) and graphite (GR) nanoparticles. The size was estimated upon
analysis by transmission electron microscopy. Zeta potential is presented as means ± standard deviation, n = 3.
DN GO GR
Average size (nm) 3–4 8–25 3–4
Zeta potential (mV) -15.8 ± 0.55 -8.8 ± 0.25 12.5 ± 0.43
doi:10.1371/journal.pone.0144821.t001
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was performed at Clinical Chemistry Analyzer Miura One (I.S.E., Guidonia, Italy). All reagents
essential for those analyses were purchased from Pointe Scientific Inc. (Canton, MI, USA). The
following parameters were examined: aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), glucose, creatinine, blood urea nitrogen (BUN),
total protein (TP), albumins, lactate dehydrogenase (LDH), and triglycerides (TG).
Liver evaluation
Liver tissue homogenate preparation. Tissue homogenates were prepared in the buffers
provided by the manufacturer (Abcam1, Cambridge, UK), separately for each of the following
analyses. The liver tissue was homogenized using TissueLyser LT (Qiagen, Germantown,
MD, USA) with a pre-frosted adapter at 50 Hz for 10 minutes, followed by centrifugation at
13 000 x g for 10 minutes at 4°C (Sorvall1 ST16, Thermo Fisher Scientific). The supernatant
(“homogenate”) was collected for analysis.
Total glutathione levels. Quantitative measurement of total glutathione levels was per-
formed using a Glutathione Detection Assay Kit—Fluorimetric (Abcam1). The assay utilizes
monochlorobimane (MCB), a dye that forms an adduct exclusively with glutathione. The dye
fluoresces blue (Ex/Em = 380nm/461nm) when bound to glutathione of the reduced (GSH) or
oxidized (GSST) form. The reaction is catalyzed by glutathione S-transferase. The GSH stan-
dard, which was provided in the kit, is used to prepare a standard curve to calculate the direct
amount of total glutathione in samples.
The homogenate was prepared as described above (10 mg of liver tissue per 100 μl of Cell
Lysis Buffer). Each sample was diluted 5 x prior to the measurement. Further steps were per-
formed in accordance with the manufacturer’s protocol. Fluorescence measurements were per-
formed employing an Infinite1 200 PRO microplate reader with i-control™ Software (Tecan
Group Ltd., Männedorf, Germany). Each sample was analyzed in triplicate.
Lipid peroxidation. Quantification of lipid peroxidation in liver tissue was performed
using a Lipid Peroxidation (MDA) Assay Kit (Abcam1). Lipid peroxidation forms malondial-
dehyde (MDA) and 4-hydroxynonenal (4-HNE) as natural byproducts. The MDA in the sam-
ple reacts with thiobarbituric acid (TBA) to generate an adduct, which can be quantified
colorimetrically (λ = 532 nm or fluorometrically (Ex/Em = 532/553 nm). The minimum detect-
able amount of MDA is 1 nmol/well and 0.1 nmol/well using the colorimetric and fluorimetric
methods, respectively.
The homogenate was prepared as described above, in lysis buffer containing butylated
hydroxytoluene (BHT) provided by the manufacturer (10 mg of liver tissue per 300 μl of MDA
Lysis Buffer). Further steps were performed in accordance with the manufacturer’s protocol,
including an additional step of filtering samples through a 0.22 μm syringe filter to eliminate
turbidity. We performed both the colorimetric and fluorometric assays to choose the most
accurate one. The measurements were performed employing an Infinite1 200 PRO microplate
reader with i-control™ Software (Tecan Group Ltd.).
C-reactive protein levels. Quantitative measurement of rat C-reactive protein (CRP) pres-
ent in liver tissue was performed using an Enzyme-Linked Immunosorbent Assay kit
(Abcam1). The provided CRP standard is used to prepare a standard curve to calculate the
direct amount of the protein in samples. The minimum detectable amount of the protein for
this assay is 0.7 ng/ml.
The homogenate was prepared as described above, in diluting buffer provided by the manu-
facturer (50 mg of liver tissue per 500 μl of buffer). The most suitable dilution of supernatant
was determined empirically by performing a series of dilutions of pooled samples, in the range
from 2 to 20 000. The 1:2000 dilution was chosen for this analysis since the detectable
Biocompatibility of Nanocarbon
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absorbance was within reader’s lower and upper limits. The assay was performed in accordance
with the manufacturer’s protocol. Absorbance measurements were performed employing an
Infinite1 200 PRO microplate reader with i-control™ Software (Tecan Group Ltd, Männedorf,
Switzerland). Each sample was analyzed in duplicate.
Analysis of multiple cytokines. For the evaluation of potential liver damage, we assessed
the levels of multiple cytokines engaged in the inflammatory state, hypersensitivity, apoptosis
and tissue regeneration. For this purpose, we used the rat Cytokine Antibody Array Membrane
(Abcam1), prepared for the simultaneous detection of 34 cytokines. The following targets can
be detected by this array: activin A, agrin, thymus chemokine-1, B7-2/CD86, CINC-1 (cyto-
kine-induced neutrophil chemoattractant 1), CINC-2α (cytokine-induced neutrophil chemoat-
tractant 2α), CINC-3 (cytokine-induced neutrophil chemoattractant 3), CNTF (ciliary
neurotrophic factor), Fas ligand, fractalkine, GM-CSF (granulocyte macrophage colony-stimu-
lating factor), ICAM-1 (intercellular adhesion molecule 1), IFN-γ (interferon γ), IL-1 R6 (inter-
leukin 1 R6), IL-10 (interleukin 10), IL-13 (interleukin 13), IL-1α (interleukin 1α), IL-1β
(interleukin 1β), IL-2 interleukin 2), IL-4 (interleukin 4), IL-6 (interleukin 6), leptin, LIX (LPS-
induced CXC chemokine), L-selectin, MCP-1 (macrophages chemoattractive protein), MIP-3α
(macrophage inflammatory protein 3α,), MMP-8 (matrix metalloprotease 8), β-NGF (β nerve
growth factor), PDGF-AA (platelet-derived growth factor AA isoform), prolactin R, RAGE
(receptor for advanced glycation end-products), TIMP-1 (metallopeptidase inhibitor), TNF-α
tumor necrosis factor α), and VEGF (vascular endothelial growth factor). IgG is printed as a
positive control.
The homogenate was prepared as described above, in diluting buffer provided by the manu-
facturer (50 mg of liver tissue per 500 μl of buffer). The total protein concentration (TPC) was
determined using a Qubit1 2.0 Fluorimeter with the Qubit Protein Assay Kit (Invitrogen, Pais-
ley, UK). Afterward, three samples from each group (4 and 12 weeks of exposure time) were
diluted and pooled to a final TPC concentration of 0.21 μg/μl. Then, membranes with printed
antibodies were incubated overnight at 4°C with pooled samples, followed by a cocktail of biotin-
conjugated antibodies (2 hours at RT), streptavidin labeled with HRP (overnight at 4°C), and
finally detection buffer for chemiluminescence. All washes between incubation periods were car-
ried out as indicated in the protocol. Incubation and wash steps were performed under gentle
rotation at 150 rpm (Mini-Shaker PSU-2T, Biosan, Riga, Latvia). Chemiluminescence detection
was performed using multiple exposure times (30 seconds to 5 minutes) with the ChemiDoc1
Imaging System with Quantity One Basic Software (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Data for glutathione, MDA and CRP levels were analyzed by two factorial analysis of variance
(ANOVA) with the Bonferroni post-hoc test, where exposure time and nanoparticle treatment
were considered as factors. For body weight gain and liver weight, blood morphology and
serum biochemical indices, one-factorial ANOVA with Duncan post-hoc test was performed.
All analyses were performed using Statgraphics1 Plus 4.1 software (StatPoint Technologies,
Warrenton, VA, USA). Differences at P 0.05 were defined as statistically significant.
Results
General health status
We examined the systemic toxicity of diamond nanoparticles (DN), graphene oxide (GO) and
graphite (GR) administrated intraperitoneally to rats for 4 weeks. The general health status of
animals was evaluated after the last injection (4 weeks) and after an additional 4 weeks (totally
12 weeks). During the total period of the experiment, all rats behaved normally. No disturbing
Biocompatibility of Nanocarbon
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symptoms of toxicity were observed. Animals were eating and drinking normally and they
were showed interest in an animal care person. All animals showed steady development and
growth. None of the examined livers were abnormally developed. There were no significant dif-
ferences in BW gain or liver weight between the groups (Table 2).
Animal dissection
Animal dissection did not reveal pathological features in the primary organs, and there were
no signs of inflammation or tissue disruption in the macroscopic images. However, a substan-
tial amount of nanoparticles was present in the body tissues of all treated groups. The nanopar-
ticles formed spherical- or oblong-shaped aggregates, which were remarkable both in rats after
4 weeks of the experiment (data previously shown in Kurantowicz et al. [28]) and in rats after
12 weeks. No differences in the amount of aggregates were noted between treated groups.
The most solid aggregates (up to 10 mm in diameter or length) were found in proximity to the
injection site, between the connective tissues of the abdominal skin, muscles and peritoneum (Fig
2). Some of those aggregates spread in a radial manner. Numerous smaller, spherical aggregates
were found among the mesentery (Fig 3), where the most solid aggregates were present in the GR
group. Some of the smaller aggregates accumulated in abdominal lipid tissue (in the area of the
injection). A few of the finest aggregates were present in the connective tissue surrounding liver.
Blood morphology and serum biochemical indices
None of the examined parameters exceeded the reference values [29,30]. It should be noted
that the range of reference intervals differs between authors and laboratories, and they are usu-
ally subjectively averaged from a variety of sources. All these parameters depend on the sex, age
and strain of rat and laboratory methods, including sampling and testing techniques. There-
fore, the range limits for the blood parameters of laboratory animals, which are presented in
the literature, cannot be treated as strict values.
Mean red blood cell corpuscular volume (MCV) was the only blood parameter with statisti-
cally significant differences, with a higher MCV in DN group in comparison with placebo
group (Table 3). However, mean values for both groups were within the reference interval.
As for the biochemical indices, there was a visible trend in the DN and GO groups for
increased AST, ALT and LDH levels (Table 4), which are widely accepted as indicators of liver
damage in different pathologic states. Nevertheless, the values remained within the reference
ranges and were not significantly different.
Total glutathione
There was significant interaction (P< 0.05) between exposure time (4 and 12 weeks) and treat-
ment (placebo, DN, GO, GR). The total glutathione level in the GO group was significantly
Table 2. Mean body weight gain (BW gain), shown as% of the initial body weight andmean liver weight (g/100g BW) in the groups treated with dia-
mond (DN), graphene oxide (GO) and graphite (GR) nanoparticles.
Placebo DN GO GR SE-pooled1 P-value
BW gain (%) 4 weeks 48.0 55.2 59.3 53.7 1.56 NS
12 weeks 105.4 97.0 118.9 99.5 4.36 NS
Liver (g/100 g of BW) 4 weeks 4.22 4.26 4.34 4.58 0.271 NS
12 weeks 3.28 3.12 3.20 3.48 0.308 NS
1Pooled standard error of means
doi:10.1371/journal.pone.0144821.t002
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different (P< 0.05) than in the placebo group. The increase was especially visible in the liver
tissue from animals kept for 12 weeks. A slight decrease in total glutathione was noticeable in
the DN group; however, the difference was not significant (Fig 4).
Lipid oxidation
There was significant interaction (P< 0.05) between exposure time (4 and 12 weeks) and treat-
ment (placebo, DN, GO, GR). The level of MDA in the DN, GO and GR groups was significantly
lower (P< 0.05) than in the placebo group. In the DN group, the MDA level increased after 12
weeks of exposure in comparison to the level of MDA in animals sacrificed after 4 weeks (Fig 5).
C-reactive protein
There was no significant interaction between exposure time (4 or 12 weeks) and treatment
(placebo, DN, GO, GR). The level of CRP in the DN group was significantly higher than in the
Fig 2. General view of dissected rat interior after 12 weeks exposure time. The right half of the rat abdomen is shown in the picture.A—Placebo, B—
diamond,C—graphene oxide,D—graphite. Arrows indicate nanoparticle aggregates located between skin and abdominal muscles in the proximity of the
injection.
doi:10.1371/journal.pone.0144821.g002
Biocompatibility of Nanocarbon
PLOS ONE | DOI:10.1371/journal.pone.0144821 December 14, 2015 8 / 18
placebo group (P< 0.05). In all groups, except GO, CRP decreased after 12 weeks of exposure
in comparison to animals sacrificed after 4 weeks; however, these differences were not statisti-
cally significant (Fig 6).
Cytokine levels
Analysis of liver tissue using the cytokine antibody membrane array did not reveal detectable
expression levels of any of 34 cytokines connected with the inflammatory state,
Fig 3. Mesenteries from dissected rats after 12 weeks exposure time, showing numerous small
aggregates of nanoparticles. A—Placebo,B—diamond, C—graphene oxide, D—graphite. The most solid
aggregates of nanoparticles are visible in the graphite group.
doi:10.1371/journal.pone.0144821.g003
Table 3. Results of bloodmorphology in rats after 12 weeks of exposure to diamond (DN), graphene oxide (GO) and graphite (GR) nanoparticles.
Placebo DN GO GR SE—pooled1 P-value
White blood cells (109/L) 2.28 1.66 2.23 1.94 1.306 NS
Lymphocytes (109/L) 1.89 1.12 1.83 1.59 1.044 NS
Monocytes (109/L) 0.06 0.09 0.04 0.06 0.068 NS
Granulocytes (109/L) 0.33 0.44 0.36 0.30 0.302 NS
Red blood cells (1012/L) 7.33 7.14 7.47 7.31 0.796 NS
Hemoglobin (g/dL) 12.7 13.1 13.2 12.9 0.37 NS
Hematocrit (%) 37.2 39.2 39.5 37.8 3.81 NS
Mean corpuscular volume(fL) 50.7* 55.0* 53.3 52.0 1.56 0.0448
Mean cell hemoglobin (pg) 17.6 18.3 16.9 18.0 1.03 NS
Mean cell hemoglobin concentration (g/dL) 34.7 33.3 31.8 34.8 1.57 NS
Red blood cells distribution width (%) 17.4 17.5 17.5 16.9 0.72 NS
Platelets (109/L) 509 422 309 540 175.7 NS
Plateletcrit (%) 0.33 0.28 0.22 0.39 0.127 NS
Mean platelet volume (fL) 6.50 6.37 7.10 7.00 0.647 NS
Platelet distribution width (%) 30.9 29.6 32.6 31.5 2.54 NS
1 Pooled standard error of means
*Value signiﬁcantly different (P< 0,05) from Placebo group
doi:10.1371/journal.pone.0144821.t003
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hypersensitivity, apoptosis or tissue regeneration. A strong signal from the IgG spots (four
spots visible in the upper left corner and two in the lower right corner) served as a positive con-
trol of proper assay performance (Fig 7).
Discussion
In the present experiment, the nanoparticles were injected intraperitoneally. The intraperito-
neal route of administration is widely used for rapid testing of toxicity. This route of adminis-
tration assures the fast absorption of a tested material, and the systemic availability is
comparable to the intravenous route. The area of the peritoneal cavity is rich in lining and
blood supply. Hence, the contact area assures a rapid absorption and potential fast toxic
responses. Moreover, this route of administration is also useful for testing agents that are not
soluble in water, like tested nanoparticles–they form a colloidal suspension, but not a water
solution.
Table 4. Serum biochemical indices in rats after 12 weeks of exposure to diamond (DN), graphene oxide (GO) and graphite (GR) nanoparticles.
Placebo DN GO GR SE—pooled1 P -value
AST (IU/L) 249 347 292 112 185.7 NS
ALT (IU/L) 67.1 88.6 90.4 54.3 48.47 NS
ALP (IU/L) 132 89 120 160 36.2 NS
Glucose (mg/dL) 210 173 199 173 32.7 NS
Creatinine (mg/dL) 0.340 0.477 0.343 0.340 0.1491 NS
BUN (mg/dL) 36.9 48.4 41.5 35.7 7.64 NS
TP (g/L) 59.0 60.0 62.0 63.7 3.366 NS
Albumin (g/L) 51.7 51.0 50.7 55.3 3.24 NS
LDH (U/L) 865 1321 1384 845 494.7 NS
TG (mg/dL) 63.0 88.2 89.3 86.5 31.11 NS
AST—aspartate aminotransferase, ALT—alanine aminotransferase, ALP—alkaline phosphatase, BUN—blood urea nitrogen, TP—total protein, LDH—
lactate dehydrogenase, TG—triglycerides
1 Pooled standard error of means
doi:10.1371/journal.pone.0144821.t004
Fig 4. Concentration of total glutathione in rat liver (mmol/g of liver tissue).Results presented as mean
± standard deviation (n = 3). * The value significantly (P < 0.05) differs from the placebo group.
doi:10.1371/journal.pone.0144821.g004
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We assumed that nanoparticles injected intraperitoneally multiple times (at a dose of
4 mg/kg/BW per injection) would at least partially accumulate within the abdominal cavity
and the tissues surrounding the site of injection and be transported into the blood circulatory
system, and finally to different organs. According to data from the literature concerning the
injection of functionalized GO, it is highly probable that most of the absorbed GO is accumu-
lated in the liver [8,31]. Furthermore, the present results and our previous measurements (28)
demonstrated an accumulation of nanoparticles in the liver serosa, which might imply that the
particles were also retained in the liver. The liver is the main detoxifying organ, participating in
storing, modifying and breaking down a broad range of substances. Many of these reactions
depend on oxidation or reduction reactions. An imbalance in redox reactions leads to oxidative
stress, which is the background for inflammatory and metabolic liver diseases [32]. Accumula-
tion of nanoparticles may also lead to chronic hepatic fibrosis [22]. Thus, the liver is an organ
that is highly exposed to damage, which could be caused by nanoparticles [33]. We decided to
examine the oxidative state of the liver by evaluating biochemical serum indices, the level of
total glutathione and lipid peroxidation, as well as possible inflammation by measuring C-reac-
tive protein level and over-expression of 34 cytokines engaged in the inflammatory state,
hypersensitivity and tissue regeneration.
The DN, GO and GR suspensions were given to animals in eight doses at three-day inter-
vals. For four weeks of the nanoparticle administration, we constantly monitored the BW,
behavior and possible signs of relapse, for example, extensive hair loss, poor water or feed
intake, apathy or aggression. Animals grew and gained weight at a normal rate, comparable in
all groups (Table 2), and their behavior remained friendly in terms of contact with a care per-
son and no disturbing symptoms were noted. Three days after the last injection, we anesthe-
tized some of animals and performed necropsy, which revealed substantial amounts of
Fig 5. Concentration of malondialdehyde (MDA) in rat liver (pmol/mg of liver tissue).Results presented
as mean ± standard deviation (n = 3). * The value significantly (P < 0.05) differs from the placebo group.
doi:10.1371/journal.pone.0144821.g005
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nanoparticles present in the abdominal wall and mesentery in the form of visible aggregates.
Small aggregates were noticeable in fat tissue and connective tissue surrounding the peritoneal
organs. This first insight into the animal body confirmed our previous presumption, that car-
bon nanoparticles may accumulate in an organism without immense toxic effects. We aimed to
determine if DN, GO and GR remaining within body cavities for a longer period of time (an
Fig 6. Concentration of C-reactive protein (CRP) in rat liver (ng/mg of liver tissue). Results presented as
mean ± standard deviation (n = 3).* The value significantly (P< 0.05) differs from the placebo group.
doi:10.1371/journal.pone.0144821.g006
Fig 7. Rat cytokine membrane array used for cytokine detection in liver tissue.On each membrane,
four spots in the upper left corner and two spots in the lower right corner represent IgG as a positive control.
(A, E) Placebo; (B, F) diamond; (C, G) graphene oxide; (D, H) graphite. Upper row (A, B, C, D) - 4 weeks
exposure, lower row (E, F, G, H) - 12 weeks exposure.
doi:10.1371/journal.pone.0144821.g007
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additional eight weeks after culling the first cohort) would induce toxicity, as well as if the
aggregates would be still present in the abdominal wall or slowly excreted. So far, reports have
mostly concentrated on the short-term effects of nanoparticles, in periods from a couple of
hours, through days to 1 month [4,9,20,34]. There are only a few reports dealing with longer
periods, from three [5,22] to five months [21]. Thus, the second cohort of animals was sacri-
ficed after 12 weeks, what constitutes a significant part of a small rodent’s lifespan. Similar to 4
weeks of exposure [28], there was no mortality and no disturbing symptoms of relapse. Nec-
ropsy revealed that, after 12 weeks of the experiment, aggregates of DN, GO and GR were still
present in large amounts within the abdominal wall (Fig 2) and mesentery (Fig 3). It should be
noted that blood vessels in the mesentery of rats in DN group were not as prominent as in
other groups. This might indicate another example of the influence of DN on blood vessels and
angiogenesis, which has been demonstrated before [3,10]; however, the effect was not measur-
able. Altogether, the results suggest that local administration of selected carbon nanoparticles
leads to significant accumulation within treated tissue, whereas other studies have shown that,
for example, GO nanoparticles administrated intravenously are mostly excreted [9,20].
Blood analysis did not reveal obvious changes in the morphology parameters (Table 3) and
all examined parameters were within range limits. Interestingly, increased levels of several
enzymes in serum, usually connected with liver damage, were noticeable, although the differ-
ences were not significant. This trend was observed for aspartate transaminase (AST), alanine
transaminase (ALT) and lactate dehydrogenase (LDH) in the DN and GR groups (Table 4).
According to clinicians, the level should be magnified over five times to be considered as a
marked increase [35]; therefore, the observed increase did not strictly confirm liver tissue
damage.
Even though DN, GO and GR are all nanoparticles of carbon allotropes, they differ at the
atomic level by the presence of various additional atoms (e.g. oxygen and hydrogen) and differ-
ent hybridization of carbon atoms. In DN, there are mostly sp3 orbitals, assuring a strong, crys-
tal form in the core, whereas in GO and GR there are mostly sp2 orbitals. The DN surface is
rich in oxygen-containing groups (e.g. -COO and -OH), which makes DN suitable for intro-
ducing surface modifications, e.g. with bioactive molecules. Also, the large number of free elec-
trons [36] makes DN a perfect donor of electrons, which may react with other radicals (e.g.
reactive oxygen species, ROS), thereby acting as a radical scavenger. GO consist of a one-atom
thick sheet, enriched with functional groups containing oxygen, like carboxylate (negatively
charged), epoxide and hydroxyl groups (polar), which give GO hydrophilic features [37]. As
well as, GO is rich in pi electrons and in sp2 orbitals, which are responsible for the hydrophobic
character of these domains [37] and are characteristic for the graphene structure, although
numerous of bonds are disrupted due to the introduction of large amounts of oxygen-contain-
ing groups [2]. We observed previously that this enrichment with oxygen significantly
improves the water solubility and stability of the solution [2]. GR has almost exclusively sp2-
bonded carbons and consists of multi-layered graphene sheets in the form of a crystal lattice,
bound by weak van der Waals forces [38]. GR, in contrast to GO, is poorly covered with oxy-
gen-containing groups and has extensively more pi electrons. All these differences cause differ-
ences in conductivity, redox potential and consequently reactivity with organic compounds in
a living organism. A common feature of all carbon nanoparticles is the abundance of electrons,
which may easily participate in redox reactions based on electron transfer.
Electrons in free radicals, bioactive substances and their metabolites (which have unpaired
electrons) play an important role in physiological processes by the electron transfer phenome-
non, which is generally a type of cell signaling [39]. Therefore, it should be expected that DN,
GO and GR, which are rich either in unpaired electrons or in electron clouds of pi bonds, will
have an effect on cellular physiology, provided that these nanoparticles have enough active
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surface. This condition is not exactly fulfilled when nanoparticles form large aggregates,
because only the outer surface of the aggregate is in contact with the surrounding tissue, what
could explain why we did not notice any signs of inflammation or tissue disruption across the
abdominal wall, in spite of enormous amounts of nanoparticles, easily visible after 12 weeks.
Numerous small, spherical aggregates of nanoparticles were located within the mesentery,
and a few of the finest aggregates were visible in the liver serosa. Mesentery blood vessels are
connected to the superior mesenteric vein, which leads to the liver via the hepatic portal vein.
Therefore, some portion of nanoparticles might be transported to the liver, which is prolific in
electron transfer processes engaged in metabolism and detoxification pathways with redox
state [40]. The presence of carbon nanoparticles in the liver after different administration
routes has been reported before [8,33,41,42]. DN, GO and GR may then have an impact on
liver function by interacting with redox reactions that maintaining the balance between pro-
duction and scavenging of reactive oxygen species (ROS) [32]. The main compound of antioxi-
dant defense against ROS and electrophiles is glutathione (GSH), which is responsible for a
balanced oxidative state [43]. GSH contains active thiol (-SH), which is oxidized upon reaction
with radicals and glutathione disulfide (GSSG) is created. GSSG can be reduced to GSH by the
GSSG reductase, ensuring a constant balance between GSH/GSSG, where GSH should account
for 98% of the total glutathione [43,44]. The liver plays a central role in GSH homeostasis [44].
We determined the total glutathione levels (GSH + GSSG) in rat liver after 4 and 12 weeks of
the experiment, and the results showed a slight decrease in glutathione in the DN group (not
statistically significant) and a significant increase in the GO group after 12 weeks (Fig 4). There
was no effect in the case of GR. The results suggest the presence of GO nanoparticles in the
liver tissue and accumulation at the molecular level in a time-dependent manner. The high
concentrations of glutathione in the GO group may result from the characteristics of GO,
structurally similar to quinones, which have carbon rings with pi electrons and functional
groups rich in oxygen. GSH is the smallest antioxidant molecule in organisms and is able to
not only react enzymatically but also to form non-enzymatic adducts with quinine-like parti-
cles, which are considered toxic to the organism [45]. Therefore, GSH might react similarly to
GO particles. Furthermore, GO may behave like an oxidant and participate in electrophile gen-
eration; these are known to increase the level of GSH via several pathways, for example, the
regulation of enzymes involved in GSH production [45]. GSH alterations are characteristic for
pathological states. GSH depletion is associated with cellular death, cytotoxicity, an excess of
radicals, oxidants and electrophiles, all of which demand de novo synthesis of GSH [46]. We
hypothesize that increased levels of GSH may be a response to accumulating GO in the men-
tioned manner. However, most pathological states are associated with GSH deficiency, not
excess [46].
Other evidence for the lack of oxidative stress in the liver was obtained with the evaluation
of lipid peroxidation by measuring malondialdehyde (MDA) levels. MDA is one of the prod-
ucts of lipid oxidation and has been widely used as a marker for this process. Lipid peroxida-
tion is caused by ROS and induces injury in cells, tissues and organs [47]. Interestingly, we
observed that MDA levels were significantly lower in all the treated groups (DN, GO and GR),
and was especially noticeable in the first cohort, culled after 4 weeks (Fig 5). This result may
suggest that DN, GO and GR do not trigger oxidative stress and, more importantly, they may
play a role in scavenging ROS, since the levels were lower than in the control (placebo) group.
Exceptionally, in the DN group, there was a prominent increase in the MDA level after 12
weeks compared to the level after 4 weeks. This was likely due to DN accumulation; this large
number of free electrons may behave in two ways, either by scavenging ROS or participating as
ROS, depending on the concentration of DN in tissue.
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Finally, we aimed to determine if DN, GO and GR triggered an inflammatory state in the
liver. C-reactive protein (CRP) is a prototypical acute phase protein, which is produced by
hepatocytes [48] in response to pro-inflammatory interleukins (IL). It is secreted into the circu-
lating peripheral blood, and is a sensitive but non-specific marker of inflammation [49]. We
measured the levels of CRP at the primary production site, showing a significant increase in
the DN group after 4 weeks, but this was not different from the placebo group after 12 weeks
(Fig 6). Since the increase was not time-dependent, it is unclear if CRP was increased because
of DN accumulation or rather if it was due to administration itself since a similar situation was
observed in the placebo group. The ultimate answer was obtained by the analysis of a number
of cytokines using an antibody membrane array, which detects cytokines engaged in the
inflammatory state, hypersensitivity, apoptosis and tissue regeneration (activin A, agrin, thy-
mus chemokine-1, B7-2/CD86, CINC-1, CINC-2α, CINC-3, CNTF, Fas ligand, fractalkine,
GM-CSF, ICAM-1, IFN-γ, IL-1 R6, IL-10, IL-13, IL-1α, IL-1β, IL-2, IL-4, IL-6, leptin, LIX, L-
selectin, MCP-1, MIP-3α, MMP-8, β-NGF, PDGF-AA, prolactin R, RAGE, TIMP-1, TNF-α,
and VEGF). The analysis ensures a robust and global insight into cytokine expression; more-
over, the assay has excellent sensitivity. The signal detected from the positive control (IgG)
confirmed proper assay performance, but we did not observe detectable expression of any of
the studied cytokines. The membranes showed no differences between the DN, GO, GR and
placebo groups (Fig 7). These results show that even when DN, GO and GR accumulated in the
liver for a prolonged period of time, they did not trigger an inflammatory state.
These results clearly reveal that the tested carbon nanoparticles accumulate in significant
amounts in proximity to the administration site for at least 12 weeks, and do not induce any
noticeable toxicity in rats. The accumulation in the form of aggregates within peritoneum
probably has prevented or reduced the systemic toxic effect. There was evidence that some of
the nanoparticles were absorbed and transported to the liver, due to alterations in oxidative
state parameters (GSH and MDA) and the CRP concentration; however, these changes were
not detrimental. Our studies allow us to suggest that materials based on DN, GO and GR
might be potential carriers in drug delivery systems, which are designed for local drug delivery
to a targeted tissue without affecting the whole organism.
Conclusions
In this study, we confirmed that DN, GO and GR are highly biocompatible and do not affect
animal health after 12 weeks of exposure time. We showed that intraperitoneally injected nano-
particles formed aggregates in the vicinity of the injection site. The aggregates of nanoparticles
injected during the first four weeks were present eight weeks later, but did not have any harm-
ful effect on surrounding tissues. The nanoparticles could be transported to the liver, but they
did not induce toxic effects. The results confirm the need for further studies on potential appli-
cability of DN, GO and GR as drug carriers for local therapies, ensuring accumulation and
slow release of drugs in a targeted tissue without harmful systemic side effects.
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